A report, titled “The Genome Revolution,” asked clients,“Is curing patients a sustainable business model?”
Goldman Sachs’ analyst Salveen Richter and colleagues answered with, “The potential to deliver ‘one shot cures’ is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies… While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”
The report went on to demonstrate the case of Gilead Sciences, which markets treatments for hepatitis C that have cure rates exceeding 90 percent. In 2015, the company’s hepatitis C treatment sales peaked at $12.5 billion. But as more people were cured and there were fewer infected individuals to spread the disease, sales began to languish. Goldman Sachs analysts estimate that the treatments will bring in less than $4 billion this year.
Remember the old drug Industry motto. Every patient cured is a customer lost.
Lamb, I agree.
Time to get rid of capitalism, greed is not good, it is selfish and irresponsible and no basis to run a society.
DS